Cargando…
Author Correction: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib
Autores principales: | Coombes, R. C., Howell, Sacha, Lord, Simon R., Kenny, Laura, Mansi, Janine, Mitri, Zahi, Palmieri, Carlo, Chap, Linnea I., Richards, Paul, Gradishar, William, Sardesai, Sagar, Melear, Jason, O’Shaughnessy, Joyce, Ward, Patrick, Chalasani, Pavani, Arkenau, Tobias, Baird, Richard D., Jeselsohn, Rinath, Ali, Simak, Clack, Glen, Bahl, Ashwani, McIntosh, Stuart, Krebs, Matthew G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10406871/ https://www.ncbi.nlm.nih.gov/pubmed/37550302 http://dx.doi.org/10.1038/s41467-023-40561-x |
Ejemplares similares
-
Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib
por: Coombes, R. C., et al.
Publicado: (2023) -
The CDK7 inhibitor CT7001 (Samuraciclib) targets proliferation pathways to inhibit advanced prostate cancer
por: Constantin, Theodora A., et al.
Publicado: (2023) -
How drug resistance takes shape
por: Jeselsohn, Rinath, et al.
Publicado: (2016) -
ESR1 fusions and therapeutic resistance in metastatic breast cancer
por: Nagy, Zsuzsanna, et al.
Publicado: (2023) -
Corrigendum: ESR1 fusions and therapeutic resistance in metastatic breast cancer
por: Nagy, Zsuzsanna, et al.
Publicado: (2023)